Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560693 | 1.00 | CHEK1 (0.45) | CHEK1IKBKB | |
| SCHEMBL560692 | 1.00 | CHEK1 (0.45) | CHEK1IKBKB | |
| SCHEMBL2286027 | 0.86 | CHEK1 (0.62) | CHEK1IKBKB | |
| SCHEMBL560379 | 0.86 | CHEK1 (0.47) | CHEK1IKBKB | |
| SCHEMBL2286032 | 0.86 | CHEK1 (0.62) | CHEK1IKBKB | |
| SCHEMBL561298 | 0.86 | CHEK1 (0.47) | CHEK1IKBKB | |
| SCHEMBL560380 | 0.86 | CHEK1 (0.47) | CHEK1IKBKB | |
| SCHEMBL560857 | 0.85 | CHEK1 (0.48) | CHEK1IKBKB | |
| SCHEMBL560856 | 0.85 | CHEK1 (0.48) | CHEK1IKBKB | |
| SCHEMBL693888 | 0.85 | CHEK1 (0.48) | CHEK1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421844-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | Chroma Therapeutics Ltd. (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035251-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LD. (GB) | 2012-02-09 | — | — | US | disclosed |
| WO-2010122294-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035251-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | IKBKE, IKBKB, NFKBIA | CHEK1 253/4885IKBKB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.